Adamax vs Selank: Frequently asked questions

Use Adamax for acute intervention windows and Selank Amidate as a background protocol. Administer Selank Amidate daily or every other day to build neuroplasticity over 2–4 weeks, then introduce Adamax as needed for acute anxiety episodes. The mechanisms don't interfere. GABAergic modulation and BDNF upregulation operate through separate pathways. But stagger administration by at least 4–6 hours to isolate effects during observation.

This suggests receptor tolerance, though Adamax is engineered to avoid the downregulation cascade seen with benzodiazepines. If anxiolytic effects diminish after 3–4 weeks of daily use, implement a 7–14 day washout period to allow GABA-A receptor density to reset. Selank Amidate does not produce tolerance because it operates through neurotrophin signaling rather than direct receptor binding. BDNF upregulation continues across months of administration.

Discard it immediately. Cloudiness or turbidity indicates bacterial contamination or peptide aggregation. Both render the solution unsafe and ineffective. Lyophilised peptides stored at −20°C before reconstitution remain stable for 12–24 months, but once mixed with bacteriostatic water, the 28-day refrigerated use window is non-negotiable. Temperature excursions above 8°C accelerate degradation and increase contamination risk.

Discard it. Peptides stored above 8°C for more than 4–6 hours undergo irreversible structural denaturation. The amino acid sequence remains intact, but tertiary structure collapses, eliminating receptor binding affinity. No visual change occurs; the solution remains clear. Potency loss is complete and undetectable without mass spectrometry. This is the single most common error in peptide research protocols. Assuming ambient temperature 'probably didn't hurt it.' It did.

Combine both peptides at standard doses. Their mechanisms do not overlap or interfere. Administer Adamax daily for chronic BDNF upregulation, and dose Selank 30 minutes before stressor exposure or behavioural tests requiring anxiolytic coverage. Published combination protocols in rodent models show additive effects without adverse interactions. This approach is valid when your experimental design includes both long-term cognitive measures (memory consolidation, neurogenesis markers) and acute stress-response behavioural assays (EPM, fear extinction).

Selank's anxiolytic action is context-dependent. It reduces stress-induced behavioural changes but does not alter baseline exploratory behaviour in non-stressed animals. If your model lacks a validated stressor (restraint, foot shock, social defeat), Selank effects will not manifest. This is a feature, not a limitation: it demonstrates specificity. For proof-of-concept validation, include a known anxiogenic challenge (elevated corticosterone, predator odour exposure) and re-test.

Request replacement peptide from the supplier before initiating research protocols. A single temperature excursion above 8°C. Even for 12–24 hours. Causes irreversible protein denaturation that neither visual inspection nor simple potency assays can reliably detect. The degraded peptide may retain partial activity, producing dose-response curves that appear normal but are shifted relative to published reference data. This creates the worst possible scenario: research proceeds without obvious failure signals, but results are non-reproducible and non-comparable to literature values. Suppliers committed to research-grade quality, including Real Peptides, maintain cold chain integrity through shipping and will replace temperature-compromised shipments rather than allowing degraded product to reach research protocols.

Adamax demonstrates faster measurable effects on feeding behaviour (2–4 hours post-administration) compared to Selank Amidate's cognitive effects, which require 5–7 days of repeated dosing. This pharmacological difference reflects their mechanisms: melanocortin receptor activation produces immediate downstream signalling through cAMP and AMPK pathways, generating measurable changes in food intake and energy expenditure within hours. GABAergic modulation and monoamine system changes require cumulative neurochemical adaptations that don't reach steady state until several days of repeated administration. Research designs requiring acute intervention effects within a single experimental session should select Adamax for metabolic endpoints or consider intranasal Selank Amidate administration, which produces faster CNS penetration than intraperitoneal routes but still requires repeated dosing for maximal effect.

Include both peptides as separate interventional arms rather than attempting to select one. Adamax vs Selank Amidate target independent receptor systems. Melanocortin and GABAergic/monoaminergic pathways operate through distinct signalling cascades with minimal crosstalk. A research design examining whether metabolic stress influences cognitive performance could employ Adamax to modulate energy homeostasis while using Selank Amidate to assess anxiety-like behaviour and learning acquisition under controlled metabolic conditions. This multi-peptide approach isolates pathway-specific contributions to complex phenotypes that single-intervention designs cannot resolve. Dosing schedules must account for each peptide's distinct half-life to maintain stable receptor occupancy throughout measurement periods.

Discard the solution and reconstitute fresh peptide before continuing the protocol. Both Adamax and Selank Amidate undergo gradual degradation beyond their stability windows. 72 hours for Adamax and 7 days for Selank Amidate at 2–8°C. Continued use of degraded solutions introduces uncontrolled potency variability that confounds research outcomes. A study measuring dose-response relationships with inconsistent active concentrations produces unreliable data regardless of otherwise rigorous methodology. Enzymatic breakdown products may also introduce biological activity distinct from the intact peptide, adding another uncontrolled variable. The cost of discarded solution is negligible compared to the cost of compromised research data.